Avidity Biosciences

Avidity Biosciences

  • Founded: 2013
  • Location: La Jolla, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Myotonic dystrophy type 1
  • Drug types: GEN, MUS, RAR, CVV
  • Lead product: AOC 1001
  • Product link: https://www.aviditybiosciences.com/pipeline/pipeline-overview/
  • Funding: $207M stock Dec 2022; $298M IPO Jun 2020; $100M C Nov 2019; $16M B Jan 2017



job board

Short description:

Antibody-Oligonucleotide Conjugates

Drug notes:

AOC 1044 Clin1/Clin2 DMD (FT); AOC 1020 Clin1/Clin2 facioscapulohumeral muscular dystrophy; 3+ undisclosed programs RD DMD, skeletal muscle conditions, rare cardiac conditions

Long description:

Avidity Biosciences is developing a new class of RNA therapies to treat rare genetic diseases. Avidity has developed an innovative pipeline built upon their Antibody Oligonucleotide Conjugate (AOCTM) platform. AOCs comprise three components: monoclonal antibodies (mAbs), a linker and siRNA. AOCs therefore combine the specificity of mAbs and the precision of oligonucleotides which enable tissue-specific and gene-specific targeting, respectively. Avidity has primarily focused on skeletal muscle diseases with AOC 1001 now in clinical trials and is looking to expand into different cells and tissues. This can be achieved through the flexibility of the AOC platform.


Avidity Biosciences
Vice President, Program Management
CSS|3 days ago
Avidity Biosciences
Director, Financial Planning & Analysis
CSS|3 days ago
Avidity Biosciences
Senior Scientist, Chemistry
CSS|5 days ago
Avidity Biosciences
Senior Medical Science Liaison/Medical Science Lia...
CSS|8 days ago
Avidity Biosciences
Senior Director/ Director, Medical Affairs
CSS|26 days ago
Avidity Biosciences
Senior Clinical Research Associate
CSS|87 days ago
Avidity Biosciences
Associate Director, Biomarker Sciences
La Jolla, CA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com